speb/financial-data huggingface dataset:
CDNA income_statement (quarterly, 2025-09-30) — +Operating Expense: 69647000.00
CDNA income_statement (quarterly, 2025-09-30) — +Total Revenue: 100055000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 11597000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 47844000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1036091000.00
CDNA cash_flow (quarterly, 2025-09-30) — Amortization Of Securities: 931000.00
CDNA income_statement (quarterly, 2025-09-30) — Basic Average Shares: 52507582.00
CDNA income_statement (quarterly, 2025-09-30) — Basic EPS: 0.03
CDNA cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 68763000.00
CDNA cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -1980000.00
CDNA cash_flow (quarterly, 2025-09-30) — Capital Expenditure Reported: -1305000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 27644000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Capital Stock: 51000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 91435000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 194217000.00
CDNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -26478000.00
CDNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: 12349000.00
CDNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 37358000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 1561000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 3863000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Inventory: -252000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -1502000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -174000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Payable: 1561000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 5424000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -4189000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Receivables: 19551000.00
CDNA cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 18858000.00
CDNA cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 19551000.00
CDNA cash_flow (quarterly, 2025-09-30) — Changes In Cash: 23229000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Common Stock: 51000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 311140000.00
CDNA cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -25563000.00
CDNA income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 30654000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 52015000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Current Assets: 300280000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 6432000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 6432000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 5763000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 5763000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 99044000.00
CDNA cash_flow (quarterly, 2025-09-30) — Depreciation: 5163000.00
CDNA cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 5163000.00
CDNA cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 5163000.00
CDNA income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 53736790.00
CDNA income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.03
CDNA income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 1675000.00
CDNA income_statement (quarterly, 2025-09-30) — EBIT: -246000.00
CDNA income_statement (quarterly, 2025-09-30) — EBITDA: 4917000.00
CDNA cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -6000.00
CDNA cash_flow (quarterly, 2025-09-30) — End Cash Position: 91986000.00
CDNA cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -26478000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Finished Goods: 9538000.00
CDNA cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 35378000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -5955000.00
CDNA income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 28429000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Goodwill: 40336000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 73782000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Gross PPE: 54892000.00
CDNA income_statement (quarterly, 2025-09-30) — Gross Profit: 69401000.00
CDNA income_statement (quarterly, 2025-09-30) — Interest Income: 2013000.00
CDNA income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 2013000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Inventory: 28328000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Invested Capital: 311140000.00
CDNA cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: 12349000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 21212000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 21212000.00
CDNA cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -25563000.00
CDNA income_statement (quarterly, 2025-09-30) — Net Income: 1675000.00
CDNA income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 1675000.00
CDNA income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 1675000.00
CDNA income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 1675000.00
CDNA income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 1675000.00
CDNA cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 1675000.00
CDNA income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 1675000.00
CDNA income_statement (quarterly, 2025-09-30) — Net Interest Income: 2013000.00
CDNA cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 14329000.00
CDNA income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 2013000.00
CDNA cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -1147000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Net PPE: 54892000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 237358000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 117000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 117000.00
CDNA income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 4917000.00
CDNA income_statement (quarterly, 2025-09-30) — Normalized Income: 1675000.00
CDNA cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 37358000.00
CDNA income_statement (quarterly, 2025-09-30) — Operating Income: -246000.00
CDNA income_statement (quarterly, 2025-09-30) — Operating Revenue: 100055000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 51407335.00
CDNA balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 29891000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -5955000.00
CDNA income_statement (quarterly, 2025-09-30) — Other Gand A: 28429000.00
CDNA income_statement (quarterly, 2025-09-30) — Other Income Expense: -107000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 33446000.00
CDNA cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 55000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 3353000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 794000.00
CDNA income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -107000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Other Properties: 54892000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 102782000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Payables: 11597000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 63612000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 23237000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
CDNA income_statement (quarterly, 2025-09-30) — Pretax Income: 1660000.00
CDNA cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 232000.00
CDNA cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -17071000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Raw Materials: 13658000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Receivables: 47844000.00
CDNA income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 30654000.00
CDNA income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 5163000.00
CDNA cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -25563000.00
CDNA income_statement (quarterly, 2025-09-30) — Research And Development: 16769000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -719047000.00
CDNA cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 31400000.00
CDNA income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 24449000.00
CDNA income_statement (quarterly, 2025-09-30) — Selling General And Administration: 52878000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Share Issued: 51407335.00
CDNA income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
CDNA cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 8418000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 311140000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 237358000.00
CDNA income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
CDNA income_statement (quarterly, 2025-09-30) — Tax Provision: -15000.00
CDNA income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.21
CDNA balance_sheet (quarterly, 2025-09-30) — Total Assets: 432307000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 311140000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Total Debt: 27644000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 311140000.00
CDNA income_statement (quarterly, 2025-09-30) — Total Expenses: 100301000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 121167000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 132027000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 22123000.00
CDNA income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -246000.00
CDNA income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
CDNA income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
CDNA balance_sheet (quarterly, 2025-09-30) — Work In Process: 5132000.00
CDNA balance_sheet (quarterly, 2025-09-30) — Working Capital: 201236000.00
CDNA income_statement (annual, 2025-12-31) — +Operating Expense: 281637000.00
CDNA income_statement (quarterly, 2025-12-31) — +Operating Expense: 78914000.00
CDNA income_statement (annual, 2025-12-31) — +Total Revenue: 379805000.00
CDNA income_statement (quarterly, 2025-12-31) — +Total Revenue: 108386000.00
CDNA balance_sheet (annual, 2025-12-31) — Accounts Payable: 9988000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 9988000.00
CDNA balance_sheet (annual, 2025-12-31) — Accounts Receivable: 42628000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 42628000.00
CDNA balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -38851000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -38851000.00
CDNA balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1043925000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1043925000.00
CDNA cash_flow (annual, 2025-12-31) — Amortization Of Securities: 1273000.00
CDNA cash_flow (quarterly, 2025-12-31) — Amortization Of Securities: -220000.00
CDNA cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 2258000.00
CDNA cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 0.00
CDNA income_statement (annual, 2025-12-31) — Basic Average Shares: 53287546.00
CDNA income_statement (quarterly, 2025-12-31) — Basic Average Shares: 51124846.00
CDNA income_statement (annual, 2025-12-31) — Basic EPS: -0.40
CDNA income_statement (quarterly, 2025-12-31) — Basic EPS: -0.08
CDNA cash_flow (annual, 2025-12-31) — Beginning Cash Position: 115274000.00
CDNA cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 91986000.00
CDNA cash_flow (annual, 2025-12-31) — Capital Expenditure: -6588000.00
CDNA cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -1971000.00
CDNA cash_flow (annual, 2025-12-31) — Capital Expenditure Reported: -5913000.00
CDNA cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -1971000.00
CDNA balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 26194000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 26194000.00
CDNA balance_sheet (annual, 2025-12-31) — Capital Stock: 50000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Capital Stock: 50000.00
CDNA balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 65429000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 65429000.00
CDNA balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 177208000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 177208000.00
CDNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -93394000.00
CDNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -12462000.00
CDNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 2158000.00
CDNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -34913000.00
CDNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 42032000.00
CDNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 21363000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Account Payable: 808000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -2378000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Accrued Expense: -4153000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 5743000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Inventory: -4959000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Inventory: 2034000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -5997000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -1542000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Payable: 808000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Payable: -2378000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -3345000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 3365000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -4413000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 3946000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Receivables: 22521000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Receivables: 5306000.00
CDNA cash_flow (annual, 2025-12-31) — Change In Working Capital: 3807000.00
CDNA cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 12167000.00
CDNA cash_flow (annual, 2025-12-31) — Changes In Account Receivables: 22521000.00
CDNA cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: 5306000.00
CDNA cash_flow (annual, 2025-12-31) — Changes In Cash: -49204000.00
CDNA cash_flow (quarterly, 2025-12-31) — Changes In Cash: -26012000.00
CDNA balance_sheet (annual, 2025-12-31) — Common Stock: 50000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Common Stock: 50000.00
CDNA balance_sheet (annual, 2025-12-31) — Common Stock Equity: 303101000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 303101000.00
CDNA cash_flow (annual, 2025-12-31) — Common Stock Payments: -87768000.00
CDNA cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -12205000.00
CDNA balance_sheet (annual, 2025-12-31) — Construction In Progress: 8280000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 8280000.00
CDNA income_statement (annual, 2025-12-31) — Cost Of Revenue: 123239000.00
CDNA income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 35512000.00
CDNA balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 27086000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 27086000.00
CDNA balance_sheet (annual, 2025-12-31) — Current Assets: 257132000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Current Assets: 257132000.00
CDNA balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 6515000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 6515000.00
CDNA balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 6515000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 6515000.00
CDNA balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 4653000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 4653000.00
CDNA balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 4653000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 4653000.00
CDNA balance_sheet (annual, 2025-12-31) — Current Liabilities: 89849000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 89849000.00
CDNA balance_sheet (annual, 2025-12-31) — Current Provisions: 3500000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Current Provisions: 3500000.00
CDNA cash_flow (annual, 2025-12-31) — Deferred Income Tax: 17000.00
CDNA cash_flow (annual, 2025-12-31) — Deferred Tax: 17000.00
CDNA cash_flow (annual, 2025-12-31) — Depreciation: 20416000.00
CDNA cash_flow (quarterly, 2025-12-31) — Depreciation: 5260000.00
CDNA cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 20416000.00
CDNA cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 5260000.00
CDNA cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 20416000.00
CDNA cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 5260000.00
CDNA income_statement (annual, 2025-12-31) — Diluted Average Shares: 53287546.00
CDNA income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 51124846.00
CDNA income_statement (annual, 2025-12-31) — Diluted EPS: -0.40
CDNA income_statement (quarterly, 2025-12-31) — Diluted EPS: -0.08
CDNA income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -21354000.00
CDNA income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -4108000.00
CDNA income_statement (annual, 2025-12-31) — EBIT: -25071000.00
CDNA income_statement (quarterly, 2025-12-31) — EBIT: -6040000.00
CDNA income_statement (annual, 2025-12-31) — EBITDA: -4655000.00
CDNA income_statement (quarterly, 2025-12-31) — EBITDA: -780000.00
CDNA cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -90000.00
CDNA cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 6000.00
CDNA cash_flow (annual, 2025-12-31) — End Cash Position: 65980000.00
CDNA cash_flow (quarterly, 2025-12-31) — End Cash Position: 65980000.00
CDNA cash_flow (annual, 2025-12-31) — Financing Cash Flow: -93394000.00
CDNA cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -12462000.00
CDNA balance_sheet (annual, 2025-12-31) — Finished Goods: 9804000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Finished Goods: 9804000.00
CDNA cash_flow (annual, 2025-12-31) — Free Cash Flow: 35444000.00
CDNA cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 19392000.00
CDNA balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -5515000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -5515000.00
CDNA income_statement (annual, 2025-12-31) — General And Administrative Expense: 107565000.00
CDNA income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 28684000.00
CDNA balance_sheet (annual, 2025-12-31) — Goodwill: 40336000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Goodwill: 40336000.00
CDNA balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 72296000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 72296000.00
CDNA balance_sheet (annual, 2025-12-31) — Gross PPE: 94582000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Gross PPE: 94582000.00
CDNA income_statement (annual, 2025-12-31) — Gross Profit: 256566000.00
CDNA income_statement (quarterly, 2025-12-31) — Gross Profit: 72874000.00
CDNA cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 284000.00
CDNA income_statement (annual, 2025-12-31) — Interest Income: 9174000.00
CDNA income_statement (quarterly, 2025-12-31) — Interest Income: 2013000.00
CDNA income_statement (annual, 2025-12-31) — Interest Income Non Operating: 9174000.00
CDNA income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 2013000.00
CDNA balance_sheet (annual, 2025-12-31) — Inventory: 26705000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Inventory: 26705000.00
CDNA balance_sheet (annual, 2025-12-31) — Invested Capital: 303101000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Invested Capital: 303101000.00
CDNA cash_flow (annual, 2025-12-31) — Investing Cash Flow: 2158000.00
CDNA cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -34913000.00
CDNA balance_sheet (annual, 2025-12-31) — Investments And Advances: 24165000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 24165000.00
CDNA balance_sheet (annual, 2025-12-31) — Leases: 18171000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Leases: 18171000.00
CDNA balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 19679000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 19679000.00
CDNA balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 19679000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 19679000.00
CDNA balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 45371000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 45371000.00
CDNA cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: 0.00
CDNA cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -87768000.00
CDNA cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: -12205000.00
CDNA income_statement (annual, 2025-12-31) — Net Income: -21354000.00
CDNA income_statement (quarterly, 2025-12-31) — Net Income: -4108000.00
CDNA income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -21354000.00
CDNA income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -4108000.00
CDNA income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -21354000.00
CDNA income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -4108000.00
CDNA income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -21354000.00
CDNA income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -4108000.00
CDNA income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -21354000.00
CDNA income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -4108000.00
CDNA cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -21354000.00
CDNA cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -4108000.00
CDNA income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -21354000.00
CDNA income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -4108000.00
CDNA cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -675000.00
CDNA cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: 0.00
CDNA income_statement (annual, 2025-12-31) — Net Interest Income: 9174000.00
CDNA income_statement (quarterly, 2025-12-31) — Net Interest Income: 2013000.00
CDNA cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 8746000.00
CDNA cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -32942000.00
CDNA income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 9174000.00
CDNA income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 2013000.00
CDNA cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -13621000.00
CDNA cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -1670000.00
CDNA balance_sheet (annual, 2025-12-31) — Net PPE: 55731000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Net PPE: 55731000.00
CDNA balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 230805000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 230805000.00
CDNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 181000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 181000.00
CDNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 181000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 181000.00
CDNA income_statement (annual, 2025-12-31) — Normalized EBITDA: 1055000.00
CDNA income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -780000.00
CDNA income_statement (annual, 2025-12-31) — Normalized Income: -16843100.00
CDNA income_statement (quarterly, 2025-12-31) — Normalized Income: -4108000.00
CDNA cash_flow (annual, 2025-12-31) — Operating Cash Flow: 42032000.00
CDNA cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 21363000.00
CDNA cash_flow (annual, 2025-12-31) — Operating Gains Losses: 48000.00
CDNA income_statement (annual, 2025-12-31) — Operating Income: -25071000.00
CDNA income_statement (quarterly, 2025-12-31) — Operating Income: -6040000.00
CDNA income_statement (annual, 2025-12-31) — Operating Revenue: 379805000.00
CDNA income_statement (quarterly, 2025-12-31) — Operating Revenue: 108386000.00
CDNA balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 50916644.00
CDNA balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 50916644.00
CDNA balance_sheet (annual, 2025-12-31) — Other Current Assets: 10591000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 10591000.00
CDNA balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -5515000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -5515000.00
CDNA income_statement (annual, 2025-12-31) — Other Gand A: 107565000.00
CDNA income_statement (quarterly, 2025-12-31) — Other Gand A: 28684000.00
CDNA income_statement (annual, 2025-12-31) — Other Income Expense: -5186000.00
CDNA income_statement (quarterly, 2025-12-31) — Other Income Expense: 264000.00
CDNA balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 31960000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 31960000.00
CDNA balance_sheet (annual, 2025-12-31) — Other Investments: 24165000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Other Investments: 24165000.00
CDNA cash_flow (annual, 2025-12-31) — Other Non Cash Items: 703000.00
CDNA cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 108000.00
CDNA balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 3904000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 3904000.00
CDNA balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 418000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 418000.00
CDNA income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 524000.00
CDNA income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 264000.00
CDNA balance_sheet (annual, 2025-12-31) — Other Properties: 22760000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Other Properties: 22760000.00
CDNA balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 111779000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 111779000.00
CDNA income_statement (annual, 2025-12-31) — Other Special Charges: 5710000.00
CDNA income_statement (quarterly, 2025-12-31) — Other Special Charges: 0.00
CDNA balance_sheet (annual, 2025-12-31) — Payables: 9988000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Payables: 9988000.00
CDNA balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 37074000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 37074000.00
CDNA balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 38107000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 38107000.00
CDNA balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
CDNA balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
CDNA income_statement (annual, 2025-12-31) — Pretax Income: -21083000.00
CDNA income_statement (quarterly, 2025-12-31) — Pretax Income: -3763000.00
CDNA cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 7995000.00
CDNA cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 1413000.00
CDNA balance_sheet (annual, 2025-12-31) — Properties: 0.00
CDNA balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
CDNA cash_flow (annual, 2025-12-31) — Purchase Of Business: 0.00
CDNA cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -675000.00
CDNA cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: 0.00
CDNA cash_flow (annual, 2025-12-31) — Purchase Of Investment: -145925000.00
CDNA cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -61574000.00
CDNA balance_sheet (annual, 2025-12-31) — Raw Materials: 13161000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Raw Materials: 13161000.00
CDNA balance_sheet (annual, 2025-12-31) — Receivables: 42628000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Receivables: 42628000.00
CDNA income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 123239000.00
CDNA income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 35512000.00
CDNA income_statement (annual, 2025-12-31) — Reconciled Depreciation: 20416000.00
CDNA income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 5260000.00
CDNA cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -87768000.00
CDNA cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: -12205000.00
CDNA income_statement (annual, 2025-12-31) — Research And Development: 71429000.00
CDNA income_statement (quarterly, 2025-12-31) — Research And Development: 19306000.00
CDNA balance_sheet (annual, 2025-12-31) — Retained Earnings: -735359000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -735359000.00
CDNA cash_flow (annual, 2025-12-31) — Sale Of Investment: 154671000.00
CDNA cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 28632000.00
CDNA income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 102643000.00
CDNA income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 30924000.00
CDNA income_statement (annual, 2025-12-31) — Selling General And Administration: 210208000.00
CDNA income_statement (quarterly, 2025-12-31) — Selling General And Administration: 59608000.00
CDNA balance_sheet (annual, 2025-12-31) — Share Issued: 50916644.00
CDNA balance_sheet (quarterly, 2025-12-31) — Share Issued: 50916644.00
CDNA income_statement (annual, 2025-12-31) — Special Income Charges: -5710000.00
CDNA income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
CDNA cash_flow (annual, 2025-12-31) — Stock Based Compensation: 34864000.00
CDNA cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 8091000.00
CDNA balance_sheet (annual, 2025-12-31) — Stockholders Equity: 303101000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 303101000.00
CDNA balance_sheet (annual, 2025-12-31) — Tangible Book Value: 230805000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 230805000.00
CDNA income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -1199100.00
CDNA income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
CDNA income_statement (annual, 2025-12-31) — Tax Provision: 271000.00
CDNA income_statement (quarterly, 2025-12-31) — Tax Provision: 345000.00
CDNA income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.21
CDNA income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.21
CDNA balance_sheet (annual, 2025-12-31) — Total Assets: 413228000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Total Assets: 413228000.00
CDNA balance_sheet (annual, 2025-12-31) — Total Capitalization: 303101000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 303101000.00
CDNA balance_sheet (annual, 2025-12-31) — Total Debt: 26194000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Total Debt: 26194000.00
CDNA balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 303101000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 303101000.00
CDNA income_statement (annual, 2025-12-31) — Total Expenses: 404876000.00
CDNA income_statement (quarterly, 2025-12-31) — Total Expenses: 114426000.00
CDNA balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 110127000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 110127000.00
CDNA balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 156096000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 156096000.00
CDNA balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 20278000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 20278000.00
CDNA income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -30781000.00
CDNA income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -6040000.00
CDNA income_statement (annual, 2025-12-31) — Total Unusual Items: -5710000.00
CDNA income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
CDNA income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -5710000.00
CDNA income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
CDNA balance_sheet (annual, 2025-12-31) — Work In Process: 3740000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Work In Process: 3740000.00
CDNA balance_sheet (annual, 2025-12-31) — Working Capital: 167283000.00
CDNA balance_sheet (quarterly, 2025-12-31) — Working Capital: 167283000.00
CDNA income_statement (quarterly, 2026-03-31) — +Operating Expense: 82273000.00
CDNA income_statement (quarterly, 2026-03-31) — +Total Revenue: 117700000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 9066000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 44585000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1052306000.00
CDNA cash_flow (quarterly, 2026-03-31) — Amortization Of Securities: 912000.00
CDNA income_statement (quarterly, 2026-03-31) — Basic Average Shares: 51151794.00
CDNA income_statement (quarterly, 2026-03-31) — Basic EPS: 0.05
CDNA cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 65980000.00
CDNA cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -3819000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 24498000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Capital Stock: 51000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 77923000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 187176000.00
CDNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -2911000.00
CDNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: 11059000.00
CDNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 4333000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -338000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -7438000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Inventory: -346000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -1559000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Payable: -338000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -7776000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -2884000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Receivables: -2078000.00
CDNA cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -14643000.00
CDNA cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: -2078000.00
CDNA cash_flow (quarterly, 2026-03-31) — Changes In Cash: 12481000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Common Stock: 51000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 313535000.00
CDNA income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 33629000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 29372000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Current Assets: 269395000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 6661000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 6661000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 5555000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 5555000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 79153000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Current Provisions: 7954000.00
CDNA cash_flow (quarterly, 2026-03-31) — Depreciation: 5318000.00
CDNA cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 5318000.00
CDNA cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 5318000.00
CDNA income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 53129928.00
CDNA income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.05
CDNA income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 2809000.00
CDNA income_statement (quarterly, 2026-03-31) — EBIT: 1798000.00
CDNA income_statement (quarterly, 2026-03-31) — EBITDA: 7116000.00
CDNA cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 13000.00
CDNA cash_flow (quarterly, 2026-03-31) — End Cash Position: 78474000.00
CDNA cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -2911000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Finished Goods: 11172000.00
CDNA cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 514000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -6272000.00
CDNA income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 30484000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Goodwill: 40336000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 72438000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Gross PPE: 54362000.00
CDNA income_statement (quarterly, 2026-03-31) — Gross Profit: 84071000.00
CDNA income_statement (quarterly, 2026-03-31) — Interest Income: 1909000.00
CDNA income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 1909000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Inventory: 26404000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Invested Capital: 313535000.00
CDNA cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: 11059000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 10901000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 17837000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 17837000.00
CDNA income_statement (quarterly, 2026-03-31) — Net Income: 2809000.00
CDNA income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 2809000.00
CDNA income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 2809000.00
CDNA income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2809000.00
CDNA income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 2809000.00
CDNA cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 2809000.00
CDNA income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 2809000.00
CDNA income_statement (quarterly, 2026-03-31) — Net Interest Income: 1909000.00
CDNA cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 14878000.00
CDNA income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 1909000.00
CDNA cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -4011000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Net PPE: 54362000.00
CDNA cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -3819000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 241097000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 130000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 130000.00
CDNA income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 7716000.00
CDNA income_statement (quarterly, 2026-03-31) — Normalized Income: 3169000.00
CDNA cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 4333000.00
CDNA cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 119000.00
CDNA income_statement (quarterly, 2026-03-31) — Operating Income: 1798000.00
CDNA income_statement (quarterly, 2026-03-31) — Operating Revenue: 117700000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 51274651.00
CDNA balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 11230000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -6272000.00
CDNA income_statement (quarterly, 2026-03-31) — Other Gand A: 30484000.00
CDNA income_statement (quarterly, 2026-03-31) — Other Income Expense: -930000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 32102000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Other Investments: 10901000.00
CDNA cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 15000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 3966000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 407000.00
CDNA income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -330000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Other Properties: 54362000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 109253000.00
CDNA income_statement (quarterly, 2026-03-31) — Other Special Charges: 600000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Payables: 9066000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 38438000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 20545000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
CDNA income_statement (quarterly, 2026-03-31) — Pretax Income: 2777000.00
CDNA cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 1100000.00
CDNA cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -39850000.00
CDNA cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -3819000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Raw Materials: 11624000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Receivables: 44585000.00
CDNA income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 33629000.00
CDNA income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 5318000.00
CDNA income_statement (quarterly, 2026-03-31) — Research And Development: 21416000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -732550000.00
CDNA cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 54728000.00
CDNA income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 30373000.00
CDNA income_statement (quarterly, 2026-03-31) — Selling General And Administration: 60857000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Share Issued: 51274651.00
CDNA income_statement (quarterly, 2026-03-31) — Special Income Charges: -600000.00
CDNA cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 9803000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 313535000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 241097000.00
CDNA income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -240000.00
CDNA income_statement (quarterly, 2026-03-31) — Tax Provision: -32000.00
CDNA income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
CDNA balance_sheet (quarterly, 2026-03-31) — Total Assets: 411062000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 313535000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Total Debt: 24498000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 313535000.00
CDNA income_statement (quarterly, 2026-03-31) — Total Expenses: 115902000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 97527000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 141667000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 18374000.00
CDNA income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 1198000.00
CDNA income_statement (quarterly, 2026-03-31) — Total Unusual Items: -600000.00
CDNA income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -600000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Work In Process: 3608000.00
CDNA balance_sheet (quarterly, 2026-03-31) — Working Capital: 190242000.00
CDNL income_statement (annual, 2023-12-31) — Amortization: 0.00
CDNL cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 3250.00
CDNL cash_flow (annual, 2023-12-31) — Amortization Of Intangibles: 3250.00
CDNL income_statement (annual, 2023-12-31) — Amortization Of Intangibles Income Statement: 0.00
CDNL income_statement (annual, 2023-12-31) — Basic Average Shares: 13218750.00
CDNL income_statement (annual, 2023-12-31) — Basic EPS: 1.56
CDNL cash_flow (annual, 2023-12-31) — Change In Other Current Assets: 971630.00
CDNL cash_flow (annual, 2023-12-31) — Change In Working Capital: -6286029.00
CDNL cash_flow (annual, 2023-12-31) — Common Stock Issuance: 0.00
CDNL cash_flow (annual, 2023-12-31) — Deferred Income Tax: 0.00
CDNL cash_flow (annual, 2023-12-31) — Deferred Tax: 0.00
CDNL cash_flow (annual, 2023-12-31) — Depreciation: 13181191.00
CDNL cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 13184441.00
CDNL cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 13184441.00
CDNL income_statement (annual, 2023-12-31) — Diluted Average Shares: 13218750.00
CDNL income_statement (annual, 2023-12-31) — Diluted EPS: 1.56
CDNL income_statement (annual, 2023-12-31) — EBITDA: 41471521.00
CDNL cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 0.00
CDNL balance_sheet (annual, 2023-12-31) — Leases: 390210.00
CDNL cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 0.00
CDNL income_statement (annual, 2023-12-31) — Normalized EBITDA: 41105602.00
CDNL balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 13218750.00
CDNL balance_sheet (annual, 2023-12-31) — Other Properties: 6190800.00
CDNL income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 199076780.00